Show simple item record

dc.contributor.advisorIslam, Farzana
dc.contributor.authorRatu, Tabassum
dc.date.accessioned2024-01-02T04:56:44Z
dc.date.available2024-01-02T04:56:44Z
dc.date.copyright2022
dc.date.issued2022-02
dc.identifier.otherID 16346022
dc.identifier.urihttp://hdl.handle.net/10361/22045
dc.descriptionThis thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.en_US
dc.descriptionCataloged from PDF version of thesis.
dc.descriptionIncludes bibliographical references (pages 39-45).
dc.description.abstractThe main aim of cancer immunotherapy treatment is to increase body’s own immune system to wreck the tumor cell, and to reboot the immune system, enabling it to attack the tumor cells.Cancer immunotherapy along with Adoptive T-cell, Immune checkpoint inhibitors, Combination treatment has apparently well-established method for treating malignant melanoma as well as different malignancy. Despite having immense clinical evidence over different cancers, immunotherapy treatment methods have demonstrated a little impact for cancer patients. In reality, thus it is evident that some of the patients shows relatively low responses because of immunological disorder. Fortunately, in recent times a combination of cancer immunotherapy along with other cancer treatments have shown tremendous result in clinical tests as well as the pre-clinical studies. In this article, four different types of immunotherapy techniques Adoptive T-cell, Monoclonal antibody, Immune checkpoint inhibitors, Vaccination have been reviewed. Furthermore, this project work attempts to look into the new directions in which immunotherapy is shifting and in future cancer patients can be benefitted.en_US
dc.description.statementofresponsibilityTabassum Ratu
dc.format.extent45 pages
dc.language.isoenen_US
dc.publisherBrac Universityen_US
dc.rightsBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.
dc.subjectT-Cellsen_US
dc.subjectImmuno-Oncologyen_US
dc.subjectAntigenen_US
dc.subjectAntibodyen_US
dc.subjectWBCen_US
dc.subjectCheckpoint inhibitoren_US
dc.subjectTumoren_US
dc.subject.lcshCancer--Treatment.
dc.titleA review of next-generation immuno-oncology agents for cancer therapy: recent dictation shifts in cancer immunotherapyen_US
dc.typeThesisen_US
dc.contributor.departmentSchool of Pharmacy, Brac University
dc.description.degreeB. Pharmacy


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record